REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria

Key Takeaways REGN and Sanofi received CHMP support to expand Dupixent for CSU in children aged 2-11 years.Phase III studies showed Dupixent cut itch and hives, and improved disease control at 24 weeks.Dupixent posted $17.8B in 2025 sales for Sanofi, while REGN logged $5.9B in collaboration revenues.Regeneron Pharmaceuticals (REGN) and its partner Sanofi (SNY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recomme ...